Senti Biosciences Holdings, Inc.SNTI

Senti Biosciences Holdings, Inc. is a pre-revenue biotech chasing logic-gated cell therapies, most notably the off-the-shelf CAR-NK candidate SENTI-202, a single-dose treatment designed to outsmart solid tumours by programming cells with synthetic gene circuits. The company trades on the promise of intelligent genetic programming, but its latest 10-Q shows revenue of just $16,000 for the quarter ending 31 March 2026, against a net loss of $4.2 million and operating cash burn of $7.5 million. Shareholders’ equity stands at $2.6 million against $35.7 million in liabilities, a balance-sheet gap that does not yet resemble the science-fiction future promised on the investor relations page.

Senti’s Gene Circuit Technology Platform claims the ability to program living cells with logic gates, a feat that would enable CAR-T and CAR-NK therapies to distinguish healthy from malignant tissue and switch on only when needed. The company’s product page showcases an elegant schematic of AND, OR and NOT gates lighting up cells like a biological computer, yet the nearest tangible output remains a Phase 1 clinical trial for SENTI-202 that is still enrolling patients. The firm’s shelf filing boasts regulatory and sales milestones worth $50 million if approval and uptake ever arrive, but the filing also concedes that the company has not yet generated meaningful product revenue.

SEC filings paint a picture of a company burning through cash while awaiting a regulatory milestone. The 10-Q for the quarter ended 31 March 2026 shows revenue of $16,000, net loss of $4.2 million, operating loss of $4.6 million, and diluted loss per share of $0.14 on 31 million shares. Cash and equivalents fell to $8.9 million, while net cash used in operating activities totalled $7.5 million. Research and development expense was $5.3 million for the quarter, and the firm spent only $196,000 on property, plant and equipment in the year ended 31 December 2025, a figure closer to a lab refurbishment budget than a scale-up plan. The company’s DEFA14A filing sets a seven-year window for FDA approval of SENTI-202 to trigger a $20 million milestone and a further $30 million if cumulative net sales exceed $200 million, targets that lie well beyond current operations.

For readers eyeing the story, the nearest source of visual context is the company’s own Gene Circuit Technology Platform image, which illustrates logic gates in cell therapy without supplying a balance sheet. The SEC companyfacts JSON for SNTI confirms the key income statement and cash-flow figures, while the submissions JSON lists the recent DEF 14A, S-3/A shelf, 13D/A and ARS filings. The platform graphic and the filings together form the public record; everything else is projection.

What changed this week is mostly paper: Senti filed an ARS on 21 July 2026, a PREM14A the same day, a DEFA14A on 15 July, an 8-K on 14 July, and a pair of S-3/A and 13D/A documents on 16 July. The filings cluster around a proposed merger that would transfer the gene-circuit pipeline-including SENTI-202-out of the current entity, a move the Schedule 13D/A describes as an acquisition of the issuer’s assets by affiliates. The board’s proxy also discloses a $20 million milestone for FDA approval by 2033 and $30 million for $200 million in sales, but neither figure changes the operating reality: the company is still a cash-burning research engine with no revenue to offset its burn.

What remains unproven is whether SENTI-202 can reach the clinic in time to save the current capital structure, and whether any acquirer will pay for a pipeline whose sole revenue line is a $16,000 contract. The evidence base does not include patient enrolment rates, interim efficacy data, partnering agreements or manufacturing readiness, so investors are left judging a story rather than auditing results. Until the Phase 1 readouts arrive-and until the balance sheet shows green shoots beyond a single government cheque-the company’s market narrative remains a set of regulatory maybes dressed in gene-circuit graphics.

The company’s S-3/A shelf statement, updated on 16 July 2026, lists the regulatory and commercial milestones but offers no timeline for cash generation or dilution mitigation. The PREM14A filed the same day outlines the board’s rationale for pursuing the merger, yet the filing does not quantify the cost of the transaction or the dilution to public shareholders. The 10-Q and 10-K remain the only sources supplying hard numbers, and those numbers describe a company whose cash runway is short and whose product runway remains hypothetical.